Insulet Q1 revenue rises 33.9% to $761.7 million; raises 2026 revenue growth outlook
Insulet reported first quarter 2026 revenue of $761.7 million, up 33.9% from a year earlier, and net income of $91.1 million, or $1.30 per diluted share, compared with $35.4 million, or $0.50, in the prior-year quarter. The company raised its full-year 2026 total revenue growth guidance to 21% to 23% in constant currency, from 20% to 22%, which points to a higher expected top line for shareholders.
Key points
- Revenue of $761.7 million, up 33.9% (30.1% in constant currency), versus $569.0 million in Q1 2025
- Net income of $91.1 million, or $1.30 per diluted share, versus $35.4 million, or $0.50; adjusted EPS of $1.42 versus $1.02
- FY 2026 total revenue growth guidance raised to 21% to 23% in constant currency, from 20% to 22% prior guidance dated February 18, 2026
- Repurchased 1.25 million shares of common stock; the release cites a voluntary medical device correction issued in March 2026 with $11.7 million of estimated warranty costs
The filing
Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.